CLEVELAND, July 28, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's first and only clinical MRI-guided radiation therapy system, announced today that the company's MRIdian® System is the focus of 40 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2016 Annual Meeting. AAPM is the largest association of medical physicists in the world and this year's meeting will be held July 31-August 4 in Washington, DC.
The MRIdian-based presentations, which include talks, posters and e-posters, will highlight topics such as adaptive radiotherapy, margin reduction, dosimetric accuracy and functional MRI for response assessment. These include experience across various clinical indications including sarcoma, lymphoma and cancers of the esophagus, pancreas, brain, lung, head and neck. Abstracts accepted by AAPM were provided by MRIdian users at five different centers: Washington University in St. Louis, Mo.; University of Wisconsin in Madison, Wis.; University of California, Los Angeles, Calif.; Seoul National University Hospital in Seoul in South Korea; and University of Miami in Miami, Fla.
Seven of this year's presentations focus specifically on MRIdian's on-table adaptive capabilities. These include two clinical studies presented by the University of Wisconsin, Madison that examine interfraction changes to illustrate the importance of on-table adaptation: one study evaluates interfraction variations in stomach deformation in gastric cancer patients, and a second study measures day-to-day changes in the distance between the pancreas and duodenum in pancreatic cancer patients. Another study from the University of Wisconsin explores MRIdian's ability to perform a single session where the patient is simulated, adapted on-table, and treated, all within 30 minutes, leveraging the system's in-room soft tissue imaging, fast auto-contouring and treatment re-planning tools.
Researchers from Washington University School of Medicine, who have been using MRIdian for adaptive therapy in patients since September 2014, will present on how to implement on-table adaptive treatments in a clinical environment and the potential role of real-time MRI-guided motion management for SBRT.
Additionally, in ViewRay's booth #5045, MRIdian users from University of California, Los Angeles; University of Miami; Washington University in St. Louis, Mo.; and University of Wisconsin in Madison, Wis., will present on their firsthand experience. Topics to be addressed include MR-IGRT implementation, gating and motion management, clinical experience and patient case studies across various indications, SBRT delivery, and use of on-table adaptive capabilities.
Clinical applications experts from ViewRay will also be available in the booth to demonstrate the treatment planning and delivery functionality of the system. The demos will showcase patient cases illustrating MRIdian image quality and industry leading Monte Carlo dose calculation to support an on-table adaptive RT workflow in less than 20 minutes.
For a full schedule of in-booth presentations, and AAPM oral and poster presentations on the MRIdian System, please visit http://www.viewray.com/aapm_2016.htm.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to presentations to be made at the AAPM 2016 Annual Meeting. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian linac, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay, Inc.